Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Positive EMA Opinion: Eli Lilly announced that the European Medicines Agency's Committee has issued a positive opinion for Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia (CLL), marking a significant step towards market access in the EU.
- Clinical Trial Results: Results from the Phase 3 BRUIN CLL-313 and CLL-314 trials demonstrate strong efficacy and tolerability of pirtobrutinib in treatment-naïve patients, which is expected to provide new treatment options for CLL patients and further enhance Lilly's market share in hematologic oncology.
- Global Approval Outlook: Following the positive opinion from the EMA, Lilly anticipates a final decision from the European Commission in the next 1-2 months, laying the groundwork for the global rollout of Jaypirca, particularly among patients who have not yet received BTK inhibitors.
- FDA Application Progress: Lilly has also submitted the trial results to the U.S. FDA, with a decision expected in the second half of 2026, which will further strengthen Jaypirca's competitive position in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1117.260
Low
950.00
Averages
1192
High
1500
Current: 1117.260
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Launches Memory Radio Station in Geneva
- Memory Radio Station Launch: Eli Lilly has launched The Memory Radio Station at the European Academy of Neurology Congress in Geneva, aiming to raise public awareness about early symptoms of Alzheimer's disease and the importance of recognizing memory changes.
- Multi-Country Tour: The initiative will travel to multiple European countries including Austria, Germany, Italy, and Belgium, engaging the public to share personal memories and enhance awareness of brain health.
- Generative AI Utilization: Visitors can participate in the Synthetic Memories project at The Memory Radio Station, using generative AI to visualize personal memories, helping individuals reconnect with moments that shape their identity.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections rising to 17.5 million by 2050, highlighting the urgent need for increased public awareness as early symptoms are often overlooked.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment
- Clinical Trial Results: Eli Lilly's BRUIN CLL-313 and BRUIN CLL-314 trials, presented at the 2025 American Society of Hematology Annual Meeting, demonstrate that pirtobrutinib shows strong efficacy and tolerability in treatment-naïve chronic lymphocytic leukemia (CLL) patients, potentially providing a new treatment option.
- Positive EMA Opinion: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), which, if granted marketing authorization, will expand its indication across all lines of therapy in the EU, significantly enhancing Eli Lilly's competitive position in the CLL treatment market.
- Global Approval Outlook: This positive opinion will be referred to the European Commission for final action, with a decision expected in the next one to two months; if approved, Jaypirca will become a treatment option for more CLL patients, further solidifying Eli Lilly's position in the global market.
- Future Development Plans: Eli Lilly has also submitted the results to the U.S. FDA for approval, with a decision anticipated in the second half of 2026, reflecting the company's strong commitment to bringing Jaypirca to market globally to meet the growing demand for CLL treatments.
See More
Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment
- Positive EMA Opinion: Eli Lilly announced that the European Medicines Agency's Committee has issued a positive opinion for Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia (CLL), marking a significant step towards market access in the EU.
- Clinical Trial Results: Results from the Phase 3 BRUIN CLL-313 and CLL-314 trials demonstrate strong efficacy and tolerability of pirtobrutinib in treatment-naïve patients, which is expected to provide new treatment options for CLL patients and further enhance Lilly's market share in hematologic oncology.
- Global Approval Outlook: Following the positive opinion from the EMA, Lilly anticipates a final decision from the European Commission in the next 1-2 months, laying the groundwork for the global rollout of Jaypirca, particularly among patients who have not yet received BTK inhibitors.
- FDA Application Progress: Lilly has also submitted the trial results to the U.S. FDA, with a decision expected in the second half of 2026, which will further strengthen Jaypirca's competitive position in the global market.
See More
Eli Lilly Launches Memory Radio Station Campaign in Geneva
- Campaign Launch Context: Eli Lilly introduces 'The Memory Radio Station' at the European Academy of Neurology Congress in Geneva, aiming to raise awareness about early symptoms of Alzheimer's disease and the importance of timely action.
- Multi-Country Tour Plan: The campaign will travel to several European countries, including Austria, Germany, Italy, and Belgium, encouraging the public to share personal memories and engage in generative AI experiences, thereby enhancing awareness of brain health.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections suggesting this number could rise to 17.5 million by 2050; however, early symptoms are often misinterpreted as normal aging.
- Collaboration and Commitment: This initiative is a result of a partnership between Eli Lilly and Domestic Data Streamers, combining scientific research on Alzheimer's with narrative arts, reflecting the company's ongoing commitment to raising public awareness and fostering early conversations.
See More
Investment Opportunities in the AI Sector
- Recursion's Drug Development Potential: Recursion Pharmaceuticals focuses on leveraging AI for drug development, and while it currently has no approved products, its candidate REC-4881 shows promise in significantly reducing polyp burden in clinical trials; if approved, this could validate its strategy and boost stock prices.
- Competitive Market Pressures: Despite Recursion's innovative approach in AI drug development, it faces intense competition from larger pharmaceutical companies that have already integrated AI into their operations, potentially impacting Recursion's market share and growth trajectory.
- Fiverr's Transformation Challenges: Fiverr is shifting from a low-cost service platform to one that handles complex projects; although its earnings per share have improved, the decline in active buyers and revenue indicates risks and uncertainties during this transition.
- Market Opportunities Amid AI Impact: Fiverr aims to enhance user engagement by focusing on complex projects that AI cannot easily accomplish, and if its new strategy succeeds, it could significantly elevate its stock price over the next five years, attracting contrarian investors' interest.
See More
Eli Lilly Launches Memory Radio Station in Geneva
- Memory Radio Station Launch: Eli Lilly has launched The Memory Radio Station at the European Academy of Neurology Congress in Geneva, aiming to raise public awareness about early symptoms of Alzheimer's disease and the importance of recognizing memory changes.
- Multi-Country Tour: The initiative will travel to multiple European countries including Austria, Germany, Italy, and Belgium, engaging the public to share personal memories and enhance awareness of brain health.
- Generative AI Utilization: Visitors can participate in the Synthetic Memories project at The Memory Radio Station, using generative AI to visualize personal memories, helping individuals reconnect with moments that shape their identity.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections rising to 17.5 million by 2050, highlighting the urgent need for increased public awareness as early symptoms are often overlooked.
See More
Estrogen Patch Shortage Impacts Hormone Therapy
- Surge in Demand: Prescriptions for estrogen patches have surged by 162% over the past two years, primarily due to the FDA's removal of a long-standing black box warning last fall, significantly impacting the supply-demand balance in the market.
- Production Challenges: Three types of estrogen patches are currently in shortage; while the FDA has not officially declared a shortage, manufacturers like Amneal are working to ramp up production to meet rising demand, highlighting the complexities and challenges in the manufacturing process.
- Exploration of Alternatives: With patches in short supply, doctors are recommending estrogen gels or customized creams from compounding pharmacies, although these alternatives are often not covered by insurance, placing an additional financial burden on patients.
- Uncertain Market Outlook: Experts predict that it may take one to two years for manufacturers to balance supply and demand, meaning women may face difficulties in treatment options during this period, adversely affecting their quality of life and health management.
See More
Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment
- Clinical Trial Results: Eli Lilly's BRUIN CLL-313 and BRUIN CLL-314 trials, presented at the 2025 American Society of Hematology Annual Meeting, demonstrate that pirtobrutinib shows strong efficacy and tolerability in treatment-naïve chronic lymphocytic leukemia (CLL) patients, potentially providing a new treatment option.
- Positive EMA Opinion: The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jaypirca (pirtobrutinib), which, if granted marketing authorization, will expand its indication across all lines of therapy in the EU, significantly enhancing Eli Lilly's competitive position in the CLL treatment market.
- Global Approval Outlook: This positive opinion will be referred to the European Commission for final action, with a decision expected in the next one to two months; if approved, Jaypirca will become a treatment option for more CLL patients, further solidifying Eli Lilly's position in the global market.
- Future Development Plans: Eli Lilly has also submitted the results to the U.S. FDA for approval, with a decision anticipated in the second half of 2026, reflecting the company's strong commitment to bringing Jaypirca to market globally to meet the growing demand for CLL treatments.
See More
Eli Lilly Receives Positive EMA Opinion for Jaypirca in CLL Treatment
- Positive EMA Opinion: Eli Lilly announced that the European Medicines Agency's Committee has issued a positive opinion for Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia (CLL), marking a significant step towards market access in the EU.
- Clinical Trial Results: Results from the Phase 3 BRUIN CLL-313 and CLL-314 trials demonstrate strong efficacy and tolerability of pirtobrutinib in treatment-naïve patients, which is expected to provide new treatment options for CLL patients and further enhance Lilly's market share in hematologic oncology.
- Global Approval Outlook: Following the positive opinion from the EMA, Lilly anticipates a final decision from the European Commission in the next 1-2 months, laying the groundwork for the global rollout of Jaypirca, particularly among patients who have not yet received BTK inhibitors.
- FDA Application Progress: Lilly has also submitted the trial results to the U.S. FDA, with a decision expected in the second half of 2026, which will further strengthen Jaypirca's competitive position in the global market.
See More
Eli Lilly Launches Memory Radio Station Campaign in Geneva
- Campaign Launch Context: Eli Lilly introduces 'The Memory Radio Station' at the European Academy of Neurology Congress in Geneva, aiming to raise awareness about early symptoms of Alzheimer's disease and the importance of timely action.
- Multi-Country Tour Plan: The campaign will travel to several European countries, including Austria, Germany, Italy, and Belgium, encouraging the public to share personal memories and engage in generative AI experiences, thereby enhancing awareness of brain health.
- Alzheimer's Disease Statistics: In 2021, Alzheimer's disease affected approximately 9.5 million people in Europe, with projections suggesting this number could rise to 17.5 million by 2050; however, early symptoms are often misinterpreted as normal aging.
- Collaboration and Commitment: This initiative is a result of a partnership between Eli Lilly and Domestic Data Streamers, combining scientific research on Alzheimer's with narrative arts, reflecting the company's ongoing commitment to raising public awareness and fostering early conversations.
See More
Investment Opportunities in the AI Sector
- Recursion's Drug Development Potential: Recursion Pharmaceuticals focuses on leveraging AI for drug development, and while it currently has no approved products, its candidate REC-4881 shows promise in significantly reducing polyp burden in clinical trials; if approved, this could validate its strategy and boost stock prices.
- Competitive Market Pressures: Despite Recursion's innovative approach in AI drug development, it faces intense competition from larger pharmaceutical companies that have already integrated AI into their operations, potentially impacting Recursion's market share and growth trajectory.
- Fiverr's Transformation Challenges: Fiverr is shifting from a low-cost service platform to one that handles complex projects; although its earnings per share have improved, the decline in active buyers and revenue indicates risks and uncertainties during this transition.
- Market Opportunities Amid AI Impact: Fiverr aims to enhance user engagement by focusing on complex projects that AI cannot easily accomplish, and if its new strategy succeeds, it could significantly elevate its stock price over the next five years, attracting contrarian investors' interest.
See More
